SLCO1B1, CYP2C9 and Fluvastatin: SLCO1B1 Normal Function

Normal SLCO1B1 transporter function. Normal myopathy risk expected based on SLCO1B1 alone.

Important Instructions: Please use CYP2C9 phenotype to select the appropriate recommendation below.

CYP2C9 Normal Metabolizer

Normal CYP2C9 enzyme activity. Normal response expected based on CYP2C9 alone.

Therapeutic Recommendation

  • Initiate standard dosing.

CYP2C9 Intermediate Metabolizer

Decreased CYP2C9 enzyme activity. Potential for increased risk of myopathy based on CYP2C9 alone.

Therapeutic Recommendation

  • Initiate ≤ 40 mg, if a dose >40 mg is needed, consider alternative statin or combination therapy.

CYP2C9 Poor Metabolizer

Little to no CYP2C9 enzyme activity. Potential for increased risk of myopathy based on CYP2C9 alone.

Therapeutic Recommendation

  • Initiate ≤ 20 mg, if a dose >20 mg is needed, consider alternative statin or combination therapy.

Back to previous page